

S/N 09/117,071



PATENT
T-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KINGSMAN ET AL. Examiner: G. LEE
Serial No.: 09/117,071 Group Art Unit: 1632
Filed: SEPTEMBER 25, 1998 Docket No.: 9192.5USWO
Title: RETROVIRAL VECTOR AND ITS USE IN GENE THERAPY

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on October _____, 2000.

By: John J. Lee
Name: John J. Lee

SUPPLEMENTAL AMENDMENT & RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In addition to the Amendment and Response mailed September 27, 2000, Applicants submit the following amendments and remarks in response to the Office Action mailed March 28, 2000.

IN THE CLAIMS

Please cancel claims 57 and 62, added by the Amendment of September 27, 2000 (without prejudice); amend claims 47, 51, 59 and 61; and add claim 63 as follows:

47. (AMENDED) A method for introducing a heterologous gene into a target cell in a subject, which comprises the following steps:

(i) conversion of a subject's cell into a producer cell [capable of producing a replication defective retroviral vector], comprising introducing into the subject's cell:
a first DNA sequence encoding a replication defective retroviral vector, which comprises
a defective retroviral genome lacking functional *env* and functional *gag*
pol genes [but having the remaining components essential for retroviral functions]; and